CD44+CD24−/low, CD44+CD24−/lowESA+, CD133+, and ALDH1+ cancer cells are CSC candidates with high tumor-initiating and cancer formation abilities in vitro and in vivo [40,41]. This evidence concerns the gene CD44 and neoplasm.